Pfizer and BioNTech to Supply Qatar with their BNT162 mRNA-based Vaccine Candidate Against SARS-CoV-2

  • Supply to be provided by the end of 2020 to 2021, subject to necessary regulatory approvals
  • Agreement is part of Pfizer’s and BioNTech’s global commitment to help address the COVID-19 pandemic
  • Pfizer and BioNTech began a Phase 2/3 safety and efficacy trial and remain on track to seek regulatory review as early as October 2020 and manufacture globally up to 100 million doses by the end of 2020 and approximately 1.3 billion doses by the end of 2021

Comments are closed.

Do NOT follow this link or you will be banned from the site!